Skip to main content
Christopher Azzoli, MD, Oncology, Providence, RI

ChristopherGAzzoliMDFASCO

Oncology Providence, RI

Thoracic Cancer

Director of Thoracic Oncology, Lifespan Cancer Institute; Associate Professor of Medicine, Brown University

Dr. Azzoli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Azzoli's full profile

Already have an account?

  • Office

    Lifespan Cancer Institute
    593 Eddy Street, George 362
    Providence, RI 02903
    Fax+1 401-444-4184

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1996 - 1999
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

  • RI State Medical License
    RI State Medical License 2018 - 2026
  • MA State Medical License
    MA State Medical License 2012 - 2025
  • NY State Medical License
    NY State Medical License 1999 - 2013
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • Boston Magazine Castle Connolly, 2013
  • Top Doctors: New York Metro Area Castle Connolly, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Oxford University Press Has Registered This DOI Pre-Publication  
    R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Press Mentions

  • Roche’s IMpower010 Trial Results Warrant Evidence on Survival Impact for Tecentriq Adoption in Non-Small Cell Lung Cancer
    Roche’s IMpower010 Trial Results Warrant Evidence on Survival Impact for Tecentriq Adoption in Non-Small Cell Lung CancerJune 2nd, 2021
  • Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake Boost
    Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019

Committees

  • Member (Steering committee), Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present